Biopharmaceutical company Clovis Oncology, Inc. announces upsizing and pricing of underwritten public offering.
On June 11, Willkie client Clovis Oncology, Inc., a biopharmaceutical company, announced the pricing of an underwritten public offering of 3,333,334 shares of its common stock at $72.00 per share. The size of the offering was upsized from $170 million to $240 million. Additionally, the underwriters have exercised a 30-day option to purchase up to an additional 486,110 shares of common stock from Clovis Oncology, bringing the total value of the offering to $275 million. J. P. Morgan Securities LLC and Credit Suisse Securities (USA) LLC are acting as joint book-running managers for the offering, which is expected to close on June 17.
Based in Boulder, Colorado, Clovis Oncology focuses on acquiring, developing and commercializing innovative anticancer agents in the U.S., Europe and additional international markets. The company targets development programs at specific subsets of cancer populations, and simultaneously develops diagnostic tools that direct a compound in development to the population that is most likely to benefit from its use.
Willkie also advised Clovis Oncology in its $130 million IPO in November 2011 and in its $75 million public offering of common stock in April 2012. The current deal was handled by Thomas Mark, Peter Jakes, William Gump, Christopher Peters, Amanda Burke, Joshua Halpern, Daniele Scalzo and Meredith Levy.